Lupin Adds Injectables Division In Japan with ¥3.1 Billion I'rom Pharmaceuticals Buyout
This article was originally published in PharmAsia News
Executive Summary
Lupin and I'rom also tie-up for Japanese clinical trial management as Indian firms see an improving generic drugs environment in Japan.